COVID-19 and immune-engaging cancer treatment

What The Viewpoint Says:

This Viewpoint discusses the challenges that arise for patients with cancer who are undergoing immune-engaging therapeutic treatment during the coronavirus disease 2019 (COVID-19) pandemic.

Authors:

Muhammad Bilal Abid, M.D., M.R.C.P., of the Medical College of Wisconsin in Milwaukee, is the corresponding author.

To access the embargoed study:

Visit our For The Media website at this link

https:/

/

media.

jamanetwork.

com/

(doi:10.1001/jamaoncol.2020.2367)

Editor’s Note:

Please see the articles for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

###

Media advisory:

The full article is linked to this news release.

Embed this link to provide your readers free access to the full-text article

This link will be live at the embargo time

https:/

/

jamanetwork.

com/

journals/

jamaoncology/

fullarticle/

10.

1001/

jamaoncol.

2020.

2367?guestAccessKey=

94f1c911-3f85-480f-869f-39448d5a8056&utm_source=

For_The_Media&utm_medium=

referral&utm_campaign=

ftm_links&utm_content=

tfl&utm_term=

052020